Deterministic modelling for transmission of Human Papillomavirus 6/11: Impact of vaccination

Mathematical Medicine and Biology

Volumn 31, Issue 2, 2014, Pages 125-149

  Ribassin Majed, Laureen ^a   Lounes, Rachid ^a   Clemençon, Stephan ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT TELECOM   (France)

Author keywords

Deterministic epidemic model; Equilibrium; Human papillomavirus; Reproduction number; Stability; Vaccination

Indexed keywords

DETERMINISTIC EPIDEMIC MODELS; DETERMINISTIC MODELING; EQUILIBRIUM; EXISTENCE AND UNIQUENESS; HUMAN PAPILLOMA VIRUS; NEXT GENERATION OPERATORS; NONLINEAR DYNAMIC MODELS; ONCOGENICS; REPRODUCTION NUMBERS; STEADY STATE STABILITY;

VACCINES;

WART VIRUS VACCINE;

BASIC REPRODUCTION NUMBER; BIOLOGICAL MODEL; COMPUTER SIMULATION; FEMALE; FRANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; MALE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; STANDARDS; TRANSMISSION;

BASIC REPRODUCTION NUMBER; COMPUTER SIMULATION; FEMALE; FRANCE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MODELS, IMMUNOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE;

EID: 84902526333     PISSN: 14778599     EISSN: 14778602     Source Type: Journal    
DOI: 10.1093/imammb/dqt001     Document Type: Article

References (35)

1. Barnabas, R. V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M. & Garnett, G. P. (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med., 3, e138.
2. Brauer, F., van den Driessche, P. & Wu, J. (2008) Mathematical Epidemiology. Berlin: Springer.
3. Diekmann, O., Heesterbeek, J. A. & Metz, J. A. (1990) On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J. Math. Biol., 28, 365-382.
4. Diekmann, O., Heesterbeek, J. A. & Roberts, M. G. (2010) The construction of next-generation matrices for compartmental epidemic models. J. R. Soc. Interface, 7, 873-885.
5. Dietz, K. (1975) Transmission and Control of Arbovirus Diseases. In D. Ludwig & K. L. Cooke (eds). Epidemiology. Philadelphia: SIAM, pp. 104-121.
6. D'Souza, G. & Dempsey, A. (2011) The role of HPV in head and neck cancer and review of the HPV vaccine. Prev. Med., 53, S5-S11.
7. Elbasha, E. H. (2006) Impact of prophylactic vaccination against human papillomavirus infection. Contemporary Mathematics 410, Mathematical Studies on Human Disease Dynamics; Emerging Paradigms and Challenges. Proceedings of the AMS-IMS-SIAM Joint Summer Research Conference on Modeling the Dynamics of Human Diseases: Emerging Paradigms and Challenges, July 17-21, 2005, Snowbird, Utah, published by Providence, RI: American Mathematical Society, pp. 113-127.
8. Elbasha, E. H. (2008) Global stability of equilibria in a two-sex HPV vaccination model. Bull. Math. Biol., 70, 894-909.
9. Elbasha, E. H., Dasbach, E. J. & Insinga, R. P. (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis, 1, 28-41.
10. Fagot, J. P., Boutrelle, A., Ricordeau, P., Weill, A. & Allemand, H. (2011) HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine, 29, 3610-3616.
11. Feng, Z., Castillo-Chavez, C. & Capurro, A. F. (2000) A model for tuberculosis with exogenous reinfection. Theor. Popul. Biol., 57, 235-247.
12. Frazer, I. (2007) Correlating immunity with protection for HPV infection. Int. J. Infect. Dis., 11(Supplement 2), S10-S16.
13. Future i/ii study group (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, 957-984.
14. Gantmacher, F. R. (1959) The Theory of Matrices. New York: Chelsea Publishers.
15. Garnett, G. P. (1997) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J.Infect. Dis., 191(Suppl. 1), S97-S106.
16. Gissman, L., Ikenberg, H., Koldovsky, U., Schnurch, H. G. & zur Hausen, H. (1983) Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl Acad. Sci. USA, 80, 560-563.
17. Hale, J. K. (1969) Ordinary Differential Equations. New York: John Wiley and Sons.
18. Hashimoto, T. & Amemiya, T. (2009) A note on a criterion for M-matrix. Comput. Math. Model., 20, 318-325.
19. Hethcote, H. W. (2000) The mathematics of infectious diseases. SIAM Rev., 42, 599-653.
20. Hughes, J. P., Garnett, G. P. & Koutsky, L. (2002) The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology, 13, 631-639.
21. Kribs-Zaleta, C. M. & Velasco-Hernández, J. X. (2000) A simple vaccination model with multiple endemic states. Math. Biosci., 164, 183-201.
22. Monsonego, J. (2008) Traité des infections et pathologies génitales à papillomavirus. Paris: Springer.
23. Muñoz, N. (2000) Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol., 19, 1-5.
24. Nielson, C.M., Harris, R. B., Flores, R., Abrahamsen, M., Papenfuss, M. R., Dunne, E. F., Markowitz, L. E. & Guiliano,A. R. (2009) Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol. Biomarkers Prev., 18, 1077-1083.
25. Nuño, M., Feng, Z., Martcheva, M. & Castillo-Chavez, C. (2005) Dynamics of two-strain influenza with isolation and partial cross-immunity. SIAM J. Appl. Math., 65, 964-982.
26. Ralston, H., Li, Z., McGlennen, R., Hellerstedt, W. & Downs Jr, L. (2009) Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am. J. Obstet. Gynecol., 200, 200-245.
27. Read, T. R. H., Hocking, J. S., Chen, M. Y., Donovan, B., Bradshaw, C. S. & Fairley, C. K. (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex. Transm. Infect., 87, 544-547.
28. Ribassin-Majed, L., Lounes, R. & Clémençon, S. (2012a) Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies. PLoS One, 7, e32251.
29. Ribassin-Majed, L., Lounes, R. & Clémençon, S. (2012b) Impact of human papillomavirus vaccination on anal cancer incidence in French women. J. Public Health Epidemiol., 4, 141-149.
30. Syrjänen, K., Hakama, M., Saarikoski, S., Väyrynen, M., Yliskoski, M., Syrjänen, S., Kataja, V. & Castrén, O. (1990) Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex. Transm. Dis., 17, 15-19.
31. Taira, A. V., Neukermans, C. P. & Sanders, G. D. (2004) Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis., 10, 1913-1923.
32. Trottier, H.,Mahmud, S., Prado, J. C.M., Sobrinho, J. S., Costa, M. C., Rohan, T. E., Villa, L. L. & Franco, E. L. (2008) Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis., 197, 1436-1447.
33. van den Driessche, P. & Watmough, J. (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci., 180, 29-48.
34. Van de Velde, N., Brisson, M. & Boily, M. C. (2010) Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine, 28, 5473-5484.
35. Zhang, X. & Liu, X. (2009) Backward bifurcation and global dynamics of an SIS epidemic model with general incidence rate and treatment. Nonlinear Anal. Real World Appl., 10, 565-575.